| E1694 {hdbayes} | R Documentation |
ECOG E1694 Trial
Description
A data set from the ECOG E1694 trial comparing the GM2-KLH/QS-21 (GMK) vaccine with high-dose interferon alfa-2b (IFN) therapy in resected high-risk melanoma patients. The study results were described in Kirkwood et al. (2001) doi:10.1200/JCO.2001.19.9.2370. This data set only includes patients without nodal metastasis and has the same variables as the E2696 data set. We can use the E2696 data as the historical data and the E1694 data as the current data.
Usage
E1694
Format
A data frame with 200 rows and 6 variables:
- failtime
relapse-free survival (RFS) times (in months)
- failind
relapse indicator, 0 = right censored, 1 = relapse
- treatment
treatment indicator, 0 = GMK, 1 = IFN
- sex
gender indicator, 0 = male, 1 = female
- age
patient age in years
- perform
ECOG performance status indicator, 0 = fully active patient, able to carry on all pre-disease performance without restriction, 1 = restricted in physically strenuous activity, but are ambulatory and able to carry out work of a light or sedentary nature
References
Kirkwood, J. M., Ibrahim, J. G., Sosman, J. A., Sondak, V. K., Agarwala, S. S., Ernstoff, M. S., and Rao, U. (2001). High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801. Journal of Clinical Oncology, 19(9), 2370–2380.